the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA
the Safety and Efficacy of Antiplatelet Therapy in Patients of CAA
Ischemic cardiovascular and cerebrovascular diseases are the main causes of death among
 people. Antiplatelet threrapy is very important for patients to prevent ischemic
 cardiovascular and cerebrovascular diseases.Ischemic cardiovascular patients of cerebral
 amyloid angiopathy (CAA) patients is as high as 20%, aspirin and clopidogrel is applied to
 prevent or treat the patient with CAA is controversial, there is no valid evidence of CAA
 crowd is safe to use of antiplatelet drugs, but progress in clinical treatment is usually
 based on patient condition for antiplatelet agents to prevent the occurrence of adverse
 events, such as blood clots.Therefore, this study is intended to be a single-center,
 prospective study of patients with ischemic cardiovascular and cerebrovascular diseases
 taking aspirin and clopidogrel, to determine whether the patients are combined with CAA , and
 to conduct a follow-up study for 12 months after team inclusion:1) The prevalence rate and
 gene spectrum of ischemic cardiovascular and cerebrovascular diseases among CAA patients
 enrolled in our hospital were analyzed;2) To explore the correlation between aspirin and
 clopidogrel drug genes and blood drug concentrations and diseases in patients with ischemic
 cardiovascular and cerebrovascular diseases complicated with CAA;3) To evaluate the efficacy
 and safety of aspirin and clopidogrel in patients with ischemic cardiovascular and
 cerebrovascular diseases who combined with CAA.
This project intends to observation of bleeding the application of antiplatelet in patients
 with CAA, so as to provide effective clinical evidence for the further application of
 clopidogrel and aspirin in patients with CAA in the future, and to provide reference basis
 for the accurate formulation of clinical treatment plans and the balance of health risks
 brought by adverse bleeding reactions.
Inclusion Criteria:

 -  Clinical diagnosis of CAA

 -  Must be able to swallow tablets

 Exclusion Criteria:

 -  Clopidogrel gene was non-CYP2C19 *1 patients.

 -  Patients with surgical thrombolysis .

 -  Patients with arteritis, aneurysms, arterial trauma and other risk factors were
 excluded.

 -  Patients with tumours, infections, fever, inflammatory diseases, post-embolization
 bleeding, peripheral vascular thrombosis or embolization, and other blood diseases
 such as hemophilia were excluded.

 -  Currently receiving treatment in another experimental device or drug study, or
 completing treatment in another experimental device or drug study ≤30 days.

 -  Patients are allergic to any of the ingredients known to be given aspirin or
 clopidogrel.

 -  Patients has an unstable medical condition, or is otherwise considered unstable by the
 investigator, based on medical history, physical examination, and routine laboratory
 tests.

 -  Patients who need to change or discontinue aspirin or clopidogrel, fail to take
 medication, or fail to come to the hospital on time due to their condition, and some
 information is missing.